{
     "PMID": "24658113",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20150120",
     "LR": "20170220",
     "IS": "1932-6203 (Electronic) 1932-6203 (Linking)",
     "VI": "9",
     "IP": "3",
     "DP": "2014",
     "TI": "EphA4 activation of c-Abl mediates synaptic loss and LTP blockade caused by amyloid-beta oligomers.",
     "PG": "e92309",
     "LID": "10.1371/journal.pone.0092309 [doi]",
     "AB": "The early stages of Alzheimer's disease are characterised by impaired synaptic plasticity and synapse loss. Here, we show that amyloid-beta oligomers (AbetaOs) activate the c-Abl kinase in dendritic spines of cultured hippocampal neurons and that c-Abl kinase activity is required for AbetaOs-induced synaptic loss. We also show that the EphA4 receptor tyrosine kinase is upstream of c-Abl activation by AbetaOs. EphA4 tyrosine phosphorylation (activation) is increased in cultured neurons and synaptoneurosomes exposed to AbetaOs, and in Alzheimer-transgenic mice brain. We do not detect c-Abl activation in EphA4-knockout neurons exposed to AbetaOs. More interestingly, we demonstrate EphA4/c-Abl activation is a key-signalling event that mediates the synaptic damage induced by AbetaOs. According to this results, the EphA4 antagonistic peptide KYL and c-Abl inhibitor STI prevented i) dendritic spine reduction, ii) the blocking of LTP induction and iii) neuronal apoptosis caused by AbetaOs. Moreover, EphA4-/- neurons or sh-EphA4-transfected neurons showed reduced synaptotoxicity by AbetaOs. Our results are consistent with EphA4 being a novel receptor that mediates synaptic damage induced by AbetaOs. EphA4/c-Abl signalling could be a relevant pathway involved in the early cognitive decline observed in Alzheimer's disease patients.",
     "FAU": [
          "Vargas, Lina M",
          "Leal, Nancy",
          "Estrada, Lisbell D",
          "Gonzalez, Adrian",
          "Serrano, Felipe",
          "Araya, Katherine",
          "Gysling, Katia",
          "Inestrosa, Nibaldo C",
          "Pasquale, Elena B",
          "Alvarez, Alejandra R"
     ],
     "AU": [
          "Vargas LM",
          "Leal N",
          "Estrada LD",
          "Gonzalez A",
          "Serrano F",
          "Araya K",
          "Gysling K",
          "Inestrosa NC",
          "Pasquale EB",
          "Alvarez AR"
     ],
     "AD": "Departamento de Biologia Celular y Molecular, Laboratorio de Senalizacion Celular, Facultad de Ciencias Biologicas, P. Universidad Catolica de Chile, Santiago, Chile. Departamento de Biologia Celular y Molecular, Laboratorio de Senalizacion Celular, Facultad de Ciencias Biologicas, P. Universidad Catolica de Chile, Santiago, Chile. Departamento de Biologia Celular y Molecular, Laboratorio de Senalizacion Celular, Facultad de Ciencias Biologicas, P. Universidad Catolica de Chile, Santiago, Chile. Departamento de Biologia Celular y Molecular, Laboratorio de Senalizacion Celular, Facultad de Ciencias Biologicas, P. Universidad Catolica de Chile, Santiago, Chile. Departamento de Biologia Celular y Molecular, Centro de Envejecimiento y Regeneracion (CARE), Facultad de Ciencias Biologicas, P. Universidad Catolica de Chile, Santiago, Chile. Departamento de Biologia Celular y Molecular, Millenium Nucleus in Stress and Addiction, Facultad de Ciencias Biologicas, P. Universidad Catolica de Chile, Santiago, Chile. Departamento de Biologia Celular y Molecular, Millenium Nucleus in Stress and Addiction, Facultad de Ciencias Biologicas, P. Universidad Catolica de Chile, Santiago, Chile. Departamento de Biologia Celular y Molecular, Centro de Envejecimiento y Regeneracion (CARE), Facultad de Ciencias Biologicas, P. Universidad Catolica de Chile, Santiago, Chile. Sanford-Burnham Medical Research Institute, La Jolla, California, United States of America. Departamento de Biologia Celular y Molecular, Laboratorio de Senalizacion Celular, Facultad de Ciencias Biologicas, P. Universidad Catolica de Chile, Santiago, Chile.",
     "LA": [
          "eng"
     ],
     "GR": [
          "P01 CA138390/CA/NCI NIH HHS/United States",
          "P01 HD025938/HD/NICHD NIH HHS/United States",
          "CA138390/CA/NCI NIH HHS/United States",
          "HD025938/HD/NICHD NIH HHS/United States"
     ],
     "PT": [
          "Journal Article",
          "Research Support, N.I.H., Extramural",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20140321",
     "PL": "United States",
     "TA": "PLoS One",
     "JT": "PloS one",
     "JID": "101285081",
     "RN": [
          "0 (Amyloid beta-Peptides)",
          "EC 2.7.10.1 (Receptor, EphA4)",
          "EC 2.7.10.2 (Proto-Oncogene Proteins c-abl)"
     ],
     "SB": "IM",
     "MH": [
          "Alzheimer Disease/pathology/physiopathology",
          "Amyloid beta-Peptides/*pharmacology/physiology",
          "Animals",
          "Cells, Cultured",
          "Dendritic Spines/metabolism",
          "Hippocampus/drug effects/metabolism",
          "Humans",
          "Long-Term Potentiation/*drug effects",
          "Mice, Knockout",
          "Neurons/drug effects/metabolism",
          "Phosphorylation",
          "Proto-Oncogene Proteins c-abl/*metabolism",
          "Rats, Sprague-Dawley",
          "Receptor, EphA4/*metabolism",
          "Synapses/pathology"
     ],
     "PMC": "PMC3962387",
     "EDAT": "2014/03/25 06:00",
     "MHDA": "2015/01/21 06:00",
     "CRDT": [
          "2014/03/25 06:00"
     ],
     "PHST": [
          "2013/10/25 00:00 [received]",
          "2014/02/21 00:00 [accepted]",
          "2014/03/25 06:00 [entrez]",
          "2014/03/25 06:00 [pubmed]",
          "2015/01/21 06:00 [medline]"
     ],
     "AID": [
          "10.1371/journal.pone.0092309 [doi]",
          "PONE-D-13-43779 [pii]"
     ],
     "PST": "epublish",
     "SO": "PLoS One. 2014 Mar 21;9(3):e92309. doi: 10.1371/journal.pone.0092309. eCollection 2014.",
     "term": "hippocampus"
}